TAC01 CLDN18.2
Alternative Names: CLDN18.2-TAC T cell; TAC-Claudin 18.2; TAC01-CLDN18.2Latest Information Update: 18 Nov 2024
Price :
$50 *
At a glance
- Originator Triumvira
- Class Antineoplastics; Gene therapies; Immunotherapies; T lymphocyte cell therapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I/II Solid tumours
Most Recent Events
- 11 Nov 2024 Efficacy and adverse events data from the phase I/II TACTIC-3 trial in Solid tumours released by Triumvira
- 15 Oct 2024 Pharmacodynamics and adverse events data from a preclinical study in Solid tumours released by Triumvira Immunologics
- 23 Aug 2023 Phase-I/II clinical trials in Solid tumours (Inoperable/Unresectable, Late-stage disease, Metastatic disease) in Canada (IV) (NCT05862324)